| HOME >> BIOLOGY >> TECHNOLOGY |
ANN ARBOR, Mich., Oct. 30 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Joyce Sutcliffe, Ph.D., as vice president of research.
Sutcliffe brings 26 years of experience in the discovery and design of new antibiotics, with particular emphasis on understanding and overcoming antibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals, where she served as vice president of biology and chief research scientist.
During her tenure at Rib-X Pharmaceuticals and previously at Pfizer and Abbott, Sutcliffe focused on leveraging knowledge about target-based resistance to help design novel antibiotics that are potent against organisms with antibiotic resistance. She also led teams that evaluated efficacy and pharmacokinetics in animal disease models to ensure safety and compatibility with other drugs.
"Antibiotic resistance drives the need for new treatments against tenacious infectious microorganisms that continue to mutate," said Sutcliffe. "For example the rampant explosion of MRSA (methicillin-resistant Staphylococcus aureus) in the community has led to a need for safe anti- infectives. These bacteria are no longer resistant to just antibiotics but have become multidrug-resistant by adding other resistance mechanisms to their armamentarium.
"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccines is particularly compelling, given the platform technology poses a very low risk of resistance while having broad antimicrobial activity against a wide range of infections," Sutcliffe said.
NanoBio's line of anti-infectives are designed to wage a two-pronged
attack against bacteria, viruses, and fungi using safe detergents along
with high-energy nanoemulsions to physically disrupt pathogen membranes and
lyse microbes, said James Baker, Jr., M.D., foun
'/>"/>
| SOURCE NanoBio Corporation Copyright©2007 PR Newswire. All rights reserved |